Italia markets open in 6 hours 35 minutes

Fluxys Belgium SA (0Q7U.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
29,47-1,33 (-4,33%)
Alla chiusura: 06:12PM BST
Schermo intero
Chiusura precedente30,80
Aperto29,47
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno29,47 - 29,47
Intervallo di 52 settimane29,47 - 29,47
Volume89
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,24
Rapporto PE (ttm)0,27
EPS (ttm)1,08
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Fluxys Belgium: Regulated information - Results for the first half of 2022

    28 September 2022 19:40 CET - Regulated information - Information on key events in the first half of 2022 and their impact on the financial situation of Fluxys Belgium Regulated turnover rose to € 287.4 million (first half of 2021: € 277.9 million) and net profit rose to € 41.1 million (first half of 2021: € 38.3 million) Infrastructure and employees operating at full speed Energy grid of the future in the making Storage over 90% filled Transported volumes on the rise Efforts to reduce our own c

  • GlobeNewswire

    Pelorus Equity Group Closes $11.8 Million Debt Financing, Enabling Juva Life to Expand Cannabis Operations, Further Clinical Research

    NEWPORT BEACH, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Pelorus Equity Group (“Pelorus”), the leading provider of commercial real estate loans for the cannabis sector, announced it has closed an $11.8 million financing with Juva Life Inc. (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution. The primary purpose of the financing, which closed on June 15, 2022, is to finan

  • GlobeNewswire

    Juva Life Secures $11.8 Million in Financing, Enabling Expansion of Cannabis Operations, Further Clinical Research

    Cannabis and Life Sciences Company Closes $11.8 Million in Non-Dilutive Debt FinancingVANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today that it has closed a non-dilutive financing of $11.8 million, enabling the Company to acquire it